Merck Serono Takes a Chance and Funds Four Academia MS Projects
After dispensing 1 million euros in grants to support research in multiple sclerosis, Merck Serono says it is committed to expanding its ties further with academics. Speaking to PharmaTimes at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Copenhagen, Andrew Galazka, chief of scientific affairs and head of autoimmune and emerging therapies at Merck Serono, said that the company has always been dedicated to fostering strong ties with academia. He said the group, which is the biopharmaceutical division of Germany's Merck KGaA, does not suffer from NIH ('not invented here') syndrome, adding that it would be "unrealistic and arrogant" to think a drug maker can come up with medical solutions working on its own.
Help employers find you! Check out all the jobs and post your resume.